Patent application number | Description | Published |
20130089542 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject. | 04-11-2013 |
20130089556 | ANTI C-MET HUMANIZED ANTIBODY AND USES THEREOF - An anti c-Met antibody, a composition comprising the antibody, and a method for preventing or treating cancer by administering the composition is provided. | 04-11-2013 |
20140086926 | METHOD OF COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES - Provided is a method of combination therapy for prevention or treatment of c-Met-induced or angiogenesis factor-induced diseases including co-administering an angiogenesis inhibitor and an anti-c-Met antibody or an antigen-binding fragment thereof to a patient. | 03-27-2014 |
20140105901 | USE OF CBL AS BIOMARKER FOR IDENTIFYING SUBJECT SUITABLE FOR TREATMENT WITH ANTI-C-MET ANTIBODY - A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods. | 04-17-2014 |
20140154251 | ANTI C-MET ANTIBODY AND USES THEREOF - An anti-c-Met antibody or antibody fragment and pharmaceutical composition comprising same, as well as a method for preventing and treating cancer by administering the antibody to a subject are provided. | 06-05-2014 |
20140294830 | METHOD OF COMBINATION THERAPY USING AN EGFR ANTAGONIST AND ANTI-C-MET ANTIBODY - A method of combination therapy for prevention and/or treatment of c-Met- and/or EGFR-induced diseases including co-administering a pharmaceutically effective amount of an EGFR antagonist and a pharmaceutically effective amount of an anti-c-Met antibody to a subject in need thereof is provided. | 10-02-2014 |
20150140014 | METHOD OF COMBINATION THERAPY USING AN ANTI-C-MET ANTIBODY - A method for prevention or treatment of a cancer, comprising co-administering (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib or a combination thereof, to a subject in need thereof, and a pharmaceutical composition comprising (a) an anti-c-Met antibody or an antigen-binding fragment thereof, and (b) at least one of lapatinib, regorafenib, vemurafenib, or a combination thereof are provided. | 05-21-2015 |
20150232573 | ANTI-EGFR/ANTI-HER2 BISPECIFIC ANTIBODIES WITH ANTI-EGFR DARPINS - An anti-EGFR/anti-HER2 bispecific antibody including an anti-EGFR DARPin and an anti-HER2 antibody, a pharmaceutical composition including the bispecific antibody, a method of preparing the bispecific antibody, and a method of reducing a side effect and/or enhancing efficacy of an anti-HER2 antibody using an anti-EGFR DARPin. | 08-20-2015 |